Results 111 to 120 of about 53,202 (260)

Incretin‐Based Medications in Women and Reproduction: A Systematic Scoping Review and Consensus Guidelines for Clinical Practice

Obesity Reviews, EarlyView.
ABSTRACT Introduction Pregnancy concurrent with incretin‐based medications is contraindicated due to unknown risk of teratogenicity, as is breastfeeding. The aim of this systematic scoping review was to investigate potential risks and benefits of incretin‐based medications in relation to preconception, pregnancy, and postnatal health, and to propose ...
Kate Maslin, Jill Shawe, Sinead Blowers, Michael Ceulemans, Kathryn Hart, Sam Schoenmakers, Amihai Rottenstreich, Heather Hopper, Mojca Jensterle, Angela C. Flynn, Sarah Siegelaar, Annick Bogaerts, Isy Douek, Nicola Heslehurst, Dries Ceulemans, Tricia Tan, Johnathan Pinkney, Martin Whyte, Shahrad Taheri, Roland Devlieger   +19 more
wiley   +1 more source

Toward “Obesityomics”: Domain‐Specific Omics in Precision Obesity Medicine with a Brief AI Perspective

Obesity Reviews, EarlyView.
ABSTRACT Background Obesity's global rise has outpaced the effectiveness of “one‐size‐fits‐all” prevention and treatment strategies. The promise of precision medicine lies in addressing the etiological and biological diversity of obesity and transforming it into actionable endotypes.
Nadia Abu Samra, Sara G. I. Suliman, Mohammed Al‐Hadad, Dorret I. Boomsma, Fadwa Alhantoobi, Maithah Alsamahi, Haneen Abufarajallah, Alia Al Tikriti, Zeyar Aung, Selena Richards, Abdulrahim Sajini, Mira Mousa, Fatima Sulaiman, Wael Osman   +13 more
wiley   +1 more source

Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review

Frontiers in Clinical Diabetes and Healthcare
Traditionally, Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), a pivotal class of drug, mimics the actions of endogenous Glucagon-like peptide-1, which have been found to be remarkable in the treatment of type 2 diabetes alongside other ...
Bisma Fatima Hammad, Nimrah Zafar, Muneeb Ullah, Syeda Jazilah Faisal, Fizzah Iftikhar, Haadia Waheed, Muhammad Waleed Muzaffar, Khadija Ahmed, Faz Ashraf, Komal Zahid, Maimoona Akhtar, Mohammed Mahmmoud Fadelallah Eljack   +11 more
doaj   +1 more source

A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity

Journal of Obesity
Obesity is considered the leading public health problem in the medical sector. The phenotype includes overweight conditions that lead to several other comorbidities that drastically decrease health.
Ibrahim Abdullah bin Ahmed
doaj   +1 more source

Adaptations of glucagon‐like peptide‐1 receptor agonist‐induced weight loss, drivers of weight regain and future directions of therapeutics

The Journal of Physiology, EarlyView.
Abstract figure legend During GLP‐1RA treatment reduced appetite and energy intake, delayed gastric emptying, decreased visceral fat mass and improved glycaemic control contribute to weight loss. After treatment cessation these benefits are partially or completely reversed, resulting in weight regain, accompanied by increased appetite and energy intake,
Camille E. M. Piguet, Rosie Nucci, Jacqueline L. Beaudry   +2 more
wiley   +1 more source

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis [PDF]

, 2012
Background Type 2 diabetes is a risk factor for Alzheimer's disease (AD), most likely linked to an impairment of insulin signalling in the brain. Therefore, drugs that enhance insulin signalling may have therapeutic potential for AD. Liraglutide (Victoza)
Hunter, Kerry, Holscher, Christian
core   +1 more source

The association between glucagon-like peptide-1 receptor agonist and rheumatoid arthritis: a population-based case–control study

Therapeutic Advances in Musculoskeletal Disease
Background: Obesity has been proposed as a risk factor for the development of rheumatoid arthritis (RA). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for weight reduction and glycemic control and have been shown to ...
Ariel Israel, Fadi Hassan, Eugene Merzon, Jalal Kurtam, Jamal Awad, Mai Assalia, Ilan Green, Shlomo Vinker, Mohammad E. Naffaa   +8 more
doaj   +1 more source

Real‐World Metabolic Improvements in Women With and Without Polyendocrine Metabolic Syndrome via a Multidisciplinary Telehealth Care Platform

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 6, November 2026.
In this retrospective cohort of 919 women with BMI ≥ 25 (557 PCOS, 362 non‐PCOS), a multidisciplinary telehealth platform produced significant improvements across eight metabolic markers over 9.6 months. Improvements were equivalent between groups despite a more adverse baseline metabolic profile in PCOS, supporting telehealth as scalable metabolic ...
Heather G. Huddleston, Rachel Blank, Nandita Sommers, Nicole Hellman, Felice Ramallo, Tiffany Pham, Karla Lindquist   +6 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonist use and clinical outcomes after posterior cervical spinal fusion for degenerative pathologies: A large cohort retrospective analysis

North American Spine Society Journal
: Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as potentially impactful agents in improving spinal fusion outcomes. While several recent studies have investigated the effect of these agents on lumbar spinal procedures ...
Christian Rajkovic, BS, Ankita Jain, MS, Mahnoor Shafi, MBBS, Oserekpamen Omobhude, BS, Tej Azad, MD, Austin Carpenter, MD, Timothy F. Witham, MD, Merritt D. Kinon, MD, John V. Wainwright, MD   +8 more
doaj   +1 more source

Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10318-10329, November 2026.
ABSTRACT Aim Lipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences. This study explores the metabolic and renal effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with genetic lipodystrophy. Patients and Methods Patients with familial partial lipodystrophy (n = 57) or congenital generalised ...
Léna Robert, Ines Belalem, Corinne Vigouroux, Hippolyte Dupuis, Marie Christine Vantyghem, Mathilde Simonson, Estelle Nobecourt, Héléna Mosbah, Sophie Beliard, Stéphanie Jellimann, Sonja Janmaat, Camille Vatier, Sophie Lamothe   +12 more
wiley   +1 more source